The impact of galsulfase enzyme replacement therapy in patients with mucopolysaccharidosis (MPS) VI with phenotypes at either end of the disease spectrum was evaluated. The MPS VI Clinical Surveillance Program (CSP) was established to collect long-term observational data from routine clinical and laboratory assessments. A subanalysis of the CSP was performed in patients with pretreatment urinary glycosaminoglycan (uGAG) levels <100 μg/mg and ≥200 μg/mg creatinine (low-and high-uGAG) who had received galsulfase for ≥6 months. uGAG, 6-minute walk test (6MWT), 3-minute stair climb test (3MSCT), pulmonary function measures, height/growth, cardiac function, and safety were evaluated. Patients with a highuGAG level at pre-treatment baseline (N = 68) showed greater impairments in endurance and pulmonary function than those with low-baseline uGAG levels (N = 39). From pre-treatment baseline, the distance walked on the 6MWT in the low-and high-uGAG groups increased by a mean (±SD) of 49 (±151) meters and 42 (±165) meters (median follow-up 5.5 and 7.7 years), respectively. The number of stairs/min climbed in the 3MSCT in the low-and high-uGAG groups increased by a mean of 18 (±33) and 30 (±45) (median follow-up 2.8 and 3.5 years), respectively. Overall, pulmonary function remained unchanged for both groups. No impact was seen on cardiac function. Galsulfase was generally well tolerated in both groups, with most adverse events being MPS-related complications unrelated to galsulfase. Results of this CSP sub-analysis suggest that galsulfase stabilizes MPS VI in the long-term and has an acceptable safety profile, regardless of baseline disease severity.
of clinical manifestations and phenotypes. Classical symptoms include musculoskeletal abnormalities, short stature, coarse facial features, dysfunctions in the pulmonary, cardiac, neurological, and gastrointestinal systems, impaired vision, and hearing loss. 1, 3 Patients with "classical" forms of MPS VI show early symptom onset, usually becoming apparent before the age of 2 years, with rapid disease progression and a life expectancy below 20 years of age without proper treatment. 1 "Non-classical" patients show a later disease onset and slower symptom progression 1 ; however, severe, life-threatening symptoms may still develop, ultimately resulting in a shortened lifespan. 1, [4] [5] [6] Although the disease spectrum of MPS VI is a continuum, patients are often categorized based on their urinary GAG (uGAG) level. Generally, uGAG levels >200 μg/mg creatinine have been linked to "classical" forms of MPS VI, 7 whereas patients with a lower uGAG level (<100 μg/mg creatinine) are considered to have a "non-classical" form of the disease. 7 Galsulfase (Naglazyme, BioMarin Pharmaceutical Inc., Novato, California) is an enzyme replacement therapy (ERT) approved for the treatment of MPS VI by the Food and Drug Administration (FDA, 2005) and European Medicines Agency (EMA, 2006). 1, 8, 9 Galsulfase clinical trials have shown consistent reductions in uGAG, significant improvements in endurance and pulmonary function and an acceptable safety profile. [10] [11] [12] [13] [14] Patients from galsulfase clinical trials and those with a confirmed diagnosis of MPS VI were later enrolled in an ongoing observational study, the MPS VI Clinical Surveillance Program (CSP), designed to collect longterm data including efficacy and safety outcomes of galsulfase for at least 15 years. 3 Baseline data of patients enrolled in the CSP (N = 132, median age 13 years) were published in 2013, which showed impaired endurance, pulmonary function and growth, as well as cardiac valve disease, hepatosplenomegaly, and compromised vision and hearing in the majority of patients. Data from 123 of these patients enrolled in the CSP and treated with ERT for up to 5 years showed uGAG reduction, and suggested improvements in endurance, pulmonary function, and hepatosplenomegaly, without changes in vision, hearing, or cardiac function. 3 To evaluate long-term impact of ERT for MPS VI at both ends of the disease spectrum, efficacy and safety data from the CSP were analyzed for patients with low-and highbaseline uGAG levels who had been receiving treatment for at least 6 months.
| METHODS

| Study design
The MPS VI CSP is an ongoing observational study, designed to collect data from routine clinical and laboratory assessments, including long-term efficacy and safety outcomes of galsulfase ERT, over at least 15 years. 3 Detailed information on the methodology of the CSP has been published previously. 3 Briefly, data collection relies on the volun- 
| Efficacy and safety evaluation
A sub-analysis of efficacy and safety outcomes was performed in patients with a pre-treatment uGAG level (prior to initiation of galsulfase treatment) of <100 μg/mg creatinine (low-uGAG) and ≥200 μg/mg creatinine (high-uGAG) who had received treatment with galsulfase for ≥6 months as of March 21, 2017 . Efficacy variables, assessed as change from pre-treatment baseline to last follow-up, were uGAG, distance walked in a 6-minute walk test (6MWT), stairs/min in a 3-minute stair climb test (3MSCT), pulmonary function, that is, forced expiratory volume in 1 second (FEV 1 ), forced vital capacity (FVC), and maximum voluntary ventilation (MVV), and growth/height. Cardiac function was also assessed, that is, presence or absence of abnormalities at the electrocardiogram (ECG) or echocardiogram (cardiac valve stenosis or regurgitation). Pre-treatment baseline was defined as the last value measured between 6 months before and 14 days after the start of ERT. GAG analysis of all urine samples was performed in a central laboratory using dimethylmethylene blue-based spectrophotometry, normalized against creatinine in order to control for variation in urine flow rates. Safety data analyzed included all adverse events (AEs) reported by the investigators. Discontinuations of galsulfase were also reported.
| Statistical methods
Data were presented using descriptive statistics, including mean, standard deviation (SD), standard error (SE) of the mean, median, and range. Outcomes were analyzed only for patients with data available.
| RESULTS
| Patient characteristics
Of the 223 patients enrolled in the CSP, 39 and 68 patients with ≥6 months ERT exposure had low (<100 μg/mg creatinine) and high (≥200 μg/mg creatinine) pre-treatment uGAG levels, respectively. Table 1 shows baseline characteristics of both patient groups. Patients with a high pretreatment uGAG level had a lower median age at diagnosis and first infusion. The proportion of patients whose race was reported to be white was slightly higher in the group of patients with a low uGAG level.
| Urinary GAG
uGAG levels normalized per mg creatinine decreased from a mean (±SD) of 54 (±28) μg/mg creatinine at pre-treatment baseline to 20 (±22) μg/mg creatinine after a median followup of 6.0 years in the low uGAG group (N = 37) and from 522 (±253) to 78 (±61) μg/mg creatinine after a median follow-up of 8.1 years in the high uGAG group (N = 64) ( Figure SS1 , Supporting Information).
| Endurance
Impairments in endurance at pre-treatment baseline were greatest in the high uGAG group. In the low uGAG group, 6MWT distance increased from a mean (±SD) of 368 (±136) meters at pre-treatment baseline to 417 (±108) meters after a median follow-up of 5.5 years (N = 23; Figure 1 ). The mean increase from pre-treatment baseline in this group was 49 (±151) meters. In the high uGAG group, 6MWT distance increased from a mean of 161 (±129) to 202 (±250) meters after a median follow-up of 7.7 years (N = 31; Figure 1 ). Mean increase from pre-treatment baseline was 42 (±165) meters.
The number of stairs/min climbed in the 3MSCT in the low uGAG group increased from a mean (±SD) of 167 (±58) at pre-treatment baseline to 184 (±54) after a median follow-up of 2.8 years (N = 12; Figure 1 ). Mean increase from pre-treatment baseline was 18 (±33) stairs/min. In the high uGAG group, the number of stairs/min climbed in the 3MSCT increased from a mean of 51 (±38) at pre-treatment baseline to 81 (±50) after a median follow-up of 3.5 years (N = 23; Figure 1 ). Mean increase from pre-treatment baseline was 30 (±45) stairs/min. 
| Pulmonary function
Pulmonary function at baseline was most severely impaired in the high uGAG group. In the low uGAG group, mean baseline FEV 1 , FVC, and MVV were 1.8 L, 2.1 L, and 40 L/min, respectively. In the high uGAG group, mean baseline FEV 1 , FVC, and MVV were 0.4 L, 0.5 L, and 14 L/min, respectively (Table 2) . Overall, pulmonary function remained stable. Improvements in FEV 1 , FVC, and MVV values were observed at last follow-up from baseline in both groups (Table 2 and Figure SS2 ).
| Growth
At pre-treatment baseline, mean standing height was 134.3 cm in the low uGAG group (N = 31) and 93.7 cm in the high uGAG group (N = 37). In the low uGAG group, mean (±SD) increases in height were 2.9 (3.7) cm after 1 year (N = 29), 7.6 (±8.0) cm after 3 years (N = 27), and 9.0 (±9.9) cm after 5 years (N = 21). In the high uGAG group, mean increases were 6.9 (±5.1) cm after 1 year (N = 32), 13.9 (±6.7) cm after 3 years (N = 32), and 17.8 (±7.0) cm after 5 years (N = 25).
| Cardiac function
In the low uGAG group, ECG results showed abnormalities in 39% at pre-treatment baseline and in 44% at follow-up (N = 18). Echocardiogram results showed abnormal septal wall motion in none of the patients at pre-treatment baseline, and in one patient (11%) at last follow-up (N = 9). Overall, the prevalence of mitral and/or aortic valve stenosis and mitral, aortic, and pulmonary valve regurgitation increased slightly from pre-treatment baseline to last follow-up ( Figure SS3A ). Ejection fraction increased slightly after a median follow-up of 5.0 years (mean % change 3.0% from a mean baseline of 69.6%, N = 14). Information on left ventricular septal thickness, left ventricular posterior wall thickness, and left ventricular shortening fraction was only available for two patients. One patient in the low uGAG group underwent valve replacement.
In the high uGAG group, ECG abnormalities were present in 43% at pre-treatment baseline and in 54% at followup (N = 35). Echocardiogram results showed abnormal septal wall motion in one patient at pre-treatment baseline (5%) and in two patients (11%) at last follow-up (N = 19). While the prevalence of mitral valve stenosis and mitral, aortic, and pulmonary valve regurgitation increased from pre-treatment baseline to last follow-up, the prevalence of aortic and pulmonary valve stenosis decreased slightly ( Figure SS3B ). Although the prevalence of tricuspid regurgitation appeared to slightly decrease as well, it should be noted that mild tricuspid regurgitation on echocardiography is sensitive to hemodynamic changes, which may have influenced the results. Ejection fraction remained stable after a median follow-up of 6.7 years (mean % change 2.0% from a mean baseline of 67.0%, N = 35), left ventricular septal thickness decreased by a mean of 11% from a mean baseline of 0.72 cm (N = 22), and left ventricular posterior wall thickness and shortening fraction remained stable after a median follow-up of 2.4 years (mean changes 2% from a mean baseline of 0.65 cm and 1% from a mean baseline of 41.5%, respectively, N = 22).
| Safety
In the low uGAG group, 34 of 39 patients reported a total of 111 AEs. These were most commonly described as nervous system-related (eg, carpal tunnel syndrome, cervical cord compression, spinal cord compression; in 13 patients or 33%), musculoskeletal-related disorders (eg, cervical spinal stenosis; in 11 patients or 28%), infections/infestations (eg, otitis media; in 11 patients or 28%), gastrointestinal disorders (eg, umbilical hernia; in nine patients or 23%), and congenital, familial, and genetic disorders (eg, developmental hip dysplasia; in five patients or 13%). Thirty one patients reported 98 serious adverse events (SAEs), of which seven (7%) in three patients were possibly or probably related to galsulfase. These treatment-related SAEs were described as seizure, gastrointestinal bleeding, hypertension (2 cases), glomerulonephritis, anaphylactic reaction, and undefined infusion-associated reaction (IAR) ( Table 3 ).
In the high uGAG group, 50 of 68 patients reported a total of 222 AEs, most commonly described as infections/ infestations (eg, device-related infection, pneumonia; in 24 patients or 35%), nervous system-related (eg, carpal tunnel syndrome, cervical cord compression, spinal cord compression; in 23 patients or 34%), musculoskeletal-related (eg, cervical spinal stenosis; in 18 patients or 26%), and respiratory-related (eg, sleep apnea; in 16 patients or 24%). A total of 199 SAEs were reported by 49 patients, of which 17 (9%), occurring in four patients, were considered possibly or probably related to galsulfase, that is, central line infection, leukemia, urticaria/pruritus, cough, undefined IAR, feeling of pressure in the chest/chest discomfort/chest pain, pale face, and nephritic and nephrotic syndrome.
One and seven patients in the low and high uGAG groups, respectively, died during the study, for reasons unrelated to galsulfase. One patient in the high uGAG group died of unknown cause. The remaining seven patients died as a result of MPS-related complications (cardiac failure, respiratory distress, cervical spinal stenosis, arrhythmia, anesthesia complication, and pneumonia).
| DISCUSSION
Since its approval over 10 years ago, galsulfase ERT has been the recommended first-line therapy for patients with MPS VI. 9 Results of clinical trials have shown significant effects of ERT on uGAG, endurance, and pulmonary function, as well as an acceptable safety profile, as assessed for up to 4.6 years. [10] [11] [12] [13] [14] The goal of the present sub-analysis of the MPS VI CSP was to assess the clinical impact and safety of long-term ERT in patients at either end of the phenotypic spectrum. For this purpose, the CSP results of two patient groups, with low and high pre-treatment uGAG levels (<100 and ≥200 μg/mg creatinine), were analyzed. The uGAG thresholds used to define both patient groups were selected based on the results of the large cross-sectional Survey Study published in 2005 by Swiedler et al., including 121 patients with MPS VI. The Survey Study showed a clear relationship between uGAG levels and clinical morbidity: normalized uGAG levels above 200 μg/mg creatinine were associated with more severe impairments in growth, endurance, pulmonary function, and joint range of motion than lower uGAG levels. Most patients greater than 20 years of age had a uGAG level below 100 μg/mg, suggesting a longer life expectancy associated with the low-uGAG group. As the goal of the present CSP sub-analysis was to characterize the impact of ERT on two opposite ends of the disease spectrum of MPS VI, a subgroup including patients with intermediate uGAG levels (100-200 μg/mg creatinine, N = 24) was not included in the analyses. Overall, the outcomes of the present study confirm the positive relationship between uGAG level and disease severity and suggest continuous benefits of treatment with galsulfase regardless of pre-treatment uGAG level. Both the low and high uGAG groups showed stabilization of endurance (6MWT, 3MSCT) and pulmonary function (FEV 1 , FVC, and MVV) after 6 to 8 years follow-up. When interpreting these results, one should consider the natural history of MPS VI, associated with a gradual deterioration of clinical manifestations with aging, and resulting in premature mortality. 7, [15] [16] [17] The long-term improvements in endurance and pulmonary function seen in the present study suggest that ERT stabilizes MPS VI disease progression in the longterm. It should be noted that pulmonary function measures were presented as absolute volumes, as percent predicted volumes cannot be calculated for this patient population because of the lack of standard reference curves for patients with a small stature. The large mean change in MVV should be interpreted with caution, as data were derived from only five patients at baseline and 13 patients at follow-up ( Table 2 ). The improvements in endurance and pulmonary function were relatively in line with published findings from the clinical trials and the Resurvey Study, a 10-year follow-up study of the previously discussed cross-sectional Survey Study. 11, 14, 18 The mean increases in the 6MWT of 49 and 42 m in the low and high uGAG group, respectively, were smaller than those reported in the clinical trials (varying from 80 to 130 m). This difference could be due to the much longer follow-up times, that is, a median of 5.5 years and 7.7 years in the low and high uGAG group, respectively, vs a mean of 1.8 to 4.6 years in the clinical trials. 11 In contrast to our findings, patients from the Resurvey Study (mean time on ERT 6.8 years) with a normalized baseline uGAG level ≥200 μg/mg creatinine (N = 32) showed no meaningful change in 6MWT distance, vs an increase of 74 m in patients with baseline uGAG <100 μg/mg creatinine (N = 14) and 40 m in patients with baseline uGAG 100-200 μg/mg creatinine (N = 8).
18
The differences between 6MWT outcomes in the high-uGAG groups of the CSP and Resurvey studies might be due to differences between patient populations. Overall, patients from the high uGAG group of the Resurvey study had a greater baseline 6MWT distance (248 vs 161 m) and were younger than those in the high uGAG group of the CSP. Taken together, this suggests that the patients from the Resurvey Study had less progressed disease at baseline, and possibly less room for improvement in the 6MWT, than those from the CSP. Similar to the CSP, the Resurvey Study showed overall increases in FEV 1 and FVC over time across baseline uGAG categories (uGAG ≤200 vs >200 μg/mg creatinine), although the greatest improvements were seen in patients below 13 years of age. 18 It should be noted that at least part of the increases seen in the 6MWT and pulmonary function tests in our study may be attributed to growth. In healthy children with growth potential, both 6MWT distance and pulmonary function measures increase with aging, along with increases in height. 14, 19 This effect might have been greater for the patients in the high uGAG group, who had a younger median age and a smaller height at the time of the first infusion than the low uGAG group (7 vs 17 years), and greater increases in height over the study period. In the low uGAG group, growth was limited, indicating that increases in pulmonary function and endurance were attributed to other mechanisms that need further investigation. No conclusions can be made regarding the impact of ERT on growth due to limited availability of growth data before treatment initiation. However, a recent study including data from the galsulfase clinical trials, the CSP, and the Resurvey Study demonstrated increases in height z-score in patients with high uGAG (>200 μg/mg creatinine) only, and up to 15 years of age. 20 The greatest improvements were seen when ERT was initiated before 6 years of age. Patients with uGAG ≤200 μg/mg creatinine showed no increases in height z-score. ERT did not seem to improve or halt progression of cardiac valve disease in the low or the high uGAG group, confirming previous findings from the Resurvey Study which showed no apparent impact on cardiac disease. These findings underline the importance of regular monitoring of cardiac function in these patients. With the exception of an 11% reduction in left ventricular septal thickness in the high uGAG group, left ventricular dimensions and ejection fraction remained relatively stable. It should be noted that the cardiac data in the CSP were derived from a limited number of patients and that the severity of valve disease or changes in severity over time were not documented. In the clinical trials, most patients had mild valve regurgitation or stenosis. 21 Both patients in the low and high uGAG groups showed a meaningful and persistent decrease in uGAG level for a median period of time of 6 and 8 years, respectively. Mean uGAG levels at last follow-up were 20 μg/mg creatinine in the low and 78 μg/mg creatinine in the high uGAG groups, respectively. As a comparison, upper limits of normal reported for healthy individuals vary from 50 μg/mg creatinine in newborns to 5 μg/mg creatinine in adults. 22 The efficacy analysis of the CSP is subject to certain limitations. Because of the voluntary nature of the disease registry, data were often incomplete or missing and followup times differed considerably between efficacy measures. In addition, variations in methods and data collection between participating sites, as well as incorrect data entries may have biased measurements. Due to the limited amount of data in the low and high uGAG groups, all age groups were combined for the analyses. Therefore, no firm conclusions can be made regarding the impact of growth on endurance and pulmonary function. Finally, the absence of an untreated control group does not allow for the quantification of the effect of ERT on the natural progression of the disease. It is important to recognize that stabilization of outcomes, or even a small decline in outcome measures, may still represent a positive result considering the progressive and deteriorating nature of MPS VI. However, this observational study is not powered to conclusively determine the significance of the observed effects.
Safety results were largely in line with those of the clinical trials. 11 The AEs reported were mostly MPS-related complications and not related to galsulfase treatment. The safety results showed a similar AE profile across the disease spectrum. Overall, tolerability of galsulfase was acceptable in both groups.
| CONCLUSIONS
Outcomes of MPS VI patients with low and high baseline uGAG levels enrolled in the CSP suggest that patients continue to benefit from treatment with galsulfase in the longterm and that galsulfase has an acceptable safety profile in both patient groups. The finding that patients from both groups showed improvements in endurance and pulmonary function after a median treatment period of at least 6 years, with a mild progression of cardiac disease, suggests that galsulfase can stabilize the natural progression of MPS VI. These results confirm previously published findings from the 10-year Resurvey Study 18 and suggest that patients with MPS VI can benefit from ERT, regardless of disease severity. Continued monitoring and inclusion of new patients in the CSP will provide further insight in how ERT impacts the natural history of MPS VI across phenotypes.
